5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | NEUTRAL | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.54▼ | 1.54▼ | 1.54▼ | 1.56▼ | 1.50▲ |
MA10 | 1.54▲ | 1.54▼ | 1.52▲ | 1.53▲ | 1.49▲ |
MA20 | 1.54▼ | 1.51▲ | 1.51▲ | 1.52▲ | 1.77▼ |
MA50 | 1.54▼ | 1.54▼ | 1.56▼ | 1.49▲ | 1.82▼ |
MA100 | 1.51▲ | 1.56▼ | 1.52▲ | 1.88▼ | 1.57▼ |
MA200 | 1.54▼ | 1.52▲ | 1.51▲ | 1.95▼ | 1.49▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | 0.006▲ | 0.008▲ | 0.005▲ | -0.023▼ |
RSI | 50.493▲ | 54.629▲ | 51.278▲ | 51.306▲ | 43.594▼ |
STOCH | 0.000▼ | 57.540 | 79.365 | 62.537 | 47.971 |
WILL %R | -100.000▼ | -27.778 | -23.810▲ | -51.732 | -53.191 |
CCI | -51.852 | 45.307 | 75.426 | 17.806 | 14.379 |
Friday, August 15, 2025 02:23 PM
PLX READ THE FULL PLX RESEARCH REPORT Second Quarter 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE:PLX) announced 2Q:25 financial and operational results in an August 14 ...
|
Thursday, August 14, 2025 09:48 AM
Management reiterated the expectation that Elfabrio royalties will exceed $100 million by 2030, based on a projected 15% to 20% market share of the Fabry disease market.
|
Thursday, August 14, 2025 05:23 AM
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
18/08/25 | 1.51 | 1.565 | 1.49 | 1.54 | 454,531 |
15/08/25 | 1.52 | 1.52 | 1.455 | 1.48 | 702,033 |
14/08/25 | 1.56 | 1.5998 | 1.51 | 1.52 | 933,766 |
13/08/25 | 1.55 | 1.6789 | 1.55 | 1.61 | 939,806 |
12/08/25 | 1.63 | 1.655 | 1.60 | 1.64 | 496,027 |
11/08/25 | 1.55 | 1.62 | 1.52 | 1.61 | 856,210 |
08/08/25 | 1.53 | 1.56 | 1.52 | 1.54 | 293,772 |
07/08/25 | 1.50 | 1.56 | 1.495 | 1.51 | 624,985 |
06/08/25 | 1.42 | 1.50 | 1.415 | 1.48 | 284,034 |
05/08/25 | 1.49 | 1.5248 | 1.42 | 1.42 | 375,384 |
|
|
||||
|
|
||||
|
|